



Canada House Cannabis Group Inc.

Formerly as Canada House Wellness Group Inc.

Condensed Interim Consolidated Financial Statements

April 30, 2023

(Expressed in thousands of Canadian dollars)

(Unaudited)

Canada House Cannabis Group Inc.
(formerly Canada House Wellness Group Inc.)

	Page
Table of Contents	
Notice of no auditor review of condensed interim consolidated financial statements	1
Condensed interim consolidated statements of financial position	2-3
Condensed interim consolidated statements of profit (loss) and comprehensive profit (loss)	4
Condensed interim consolidated statements of changes in shareholders' equity (deficiency)	5
Condensed interim consolidated statements of cash flows	6
Notes to condensed interim consolidated financial statements	7-33

Notice of no auditor review of condensed interim consolidated financial statements

Under Part 4, subsection 4.3(3)(a) of National Instrument 51-102 – Continuous Disclosure Obligations, if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of Canada House Cannabis Group Inc. (the “Company”) have been prepared by and are the responsibility of the Company’s management.

The Company’s independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity’s auditor.

Canada House Cannabis Group Inc.
(formerly Canada House Wellness Group Inc.)
Condensed Interim Consolidated Statements of Financial Position
(Unaudited - Expressed in thousands of Canadian Dollars, except for shares and per share amounts)

	Note	April 30, 2023	July 31, 2022
ASSETS			
Current assets:			
Cash		511	450
Trade and other receivables	5	7,762	3,058
Inventory	6	2,910	3,601
Biological assets	7	1,066	84
Prepaid expenses and deposits		615	534
		12,864	7,727
Property, plant and equipment, net	9	11,480	12,954
Investment in associates	8	6,140	-
Right-of-use assets, net		2,302	2,182
Intangible assets, net		7,646	7,640
Goodwill	4	3,546	3,546
Total assets		43,978	34,049
LIABILITIES			
Current liabilities:			
Trade and other payables		11,550	11,574
Due to related parties	11	-	3
Current portion of lease liability		547	378
Current portion of debentures	13	627	1,050
Mortgage payable	14	1,956	2,000
Promissory notes	10	4,167	76
Borrowings	12	2,573	1,766
Consideration payable	4	197	197
		21,617	17,044
Non-current liabilities			
Lease liability		1,885	1,910
Borrowings	12	1,917	2,160
Promissory notes	4,10,11	7,817	10,790
Consideration payable	4	195	195
Debentures	13	4,485	3,717
Financial instruments liabilities	13	3,635	-
Deferred tax liabilities	4	1,996	1,986
Total liabilities		43,547	37,802

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Canada House Cannabis Group Inc.
(formerly Canada House Wellness Group Inc.)
Condensed Interim Consolidated Statements of Financial Position (continued)
(Unaudited - Expressed in thousands of Canadian Dollars, except for shares and per share amounts)

	Note	April 30, 2023	July 31, 2022
SHAREHOLDERS' EQUITY (DEFICIENCY)			
Share capital	15	55,106	48,685
Equity component of convertible debentures	13,15	670	2,174
Contributed surplus	15,16	12,555	14,287
Deficit		(67,900)	(68,899)
Total shareholders' equity (deficiency)		431	(3,753)
Total liabilities and shareholders' equity (deficiency)		43,978	34,049

Nature of operations and going concern (note 1)
Commitments and contingencies (note 20)
Subsequent events (note 24)

Approved by the Board:
"Dennis Moir" Chair of the Board

"Norman Betts" Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Canada House Cannabis Group Inc.
(formerly Canada House Wellness Group Inc.)
Condensed Interim Consolidated Statements of Profit (Loss) and Comprehensive Profit (Loss)
(Unaudited - Expressed in thousands of Canadian Dollars, except for shares and per share amounts)
For the three and nine months ended April 30, 2023 and 2022

	Note	Three months ended		Nine months ended	
		April 30 2023	April 30 2022	April 30 2023	April 30 2022
		\$000's	\$000's	\$000's	\$000's
Revenue					
Referral revenue		1,314	1,316	4,008	3,974
Product revenue		6,279	4,387	17,330	14,893
License revenue and other		2,149	230	3,323	433
Less excise tax		(397)	(436)	(1,516)	(2,521)
Net revenue		9,345	5,497	23,145	16,779
Cost of sales	6	3,260	2,750	8,107	7,977
Inventory impairment	6	-	1,259	-	2,996
Gross profit before fair value adjustments		6,085	1,488	15,038	5,806
Realized loss (gain) on sale of inventory		1,137	(5)	2,236	898
Unrealized (gain) loss on biological assets	7	(1,217)	88	(3,416)	278
Gross profit		6,165	1,405	16,218	4,630
Expenses					
General and administrative	19	2,665	2,241	7,273	6,803
Sales and marketing	19	389	259	1,114	1,142
Share-based compensation	16	-	53	23	255
Right-of-use assets amortization		116	90	356	273
Depreciation and amortization	9	462	263	1,429	755
		3,632	2,906	10,195	9,228
Profit (loss) from operations		2,533	(1,501)	6,023	(4,598)
Finance costs	17	1,471	810	3,737	2,727
Change in fair value of financial instruments	13	(204)	-	(469)	-
Loss (gain) on debt settlement and modifications	10	-	(75)	701	(75)
Loss on assets disposal		20	-	20	-
Share of loss from investment in associates	8	540	-	611	-
Other expenses		-	-	-	2
Profit (loss) before income taxes		706	(2,236)	1,423	(7,252)
Recovery of income taxes		(50)	(90)	(29)	(30)
Net profit (loss) and comprehensive profit (loss) for the period		756	(2,146)	1,452	(7,222)
Weighted average number of shares outstanding					
- basic and diluted		45,999,560	22,788,427	43,205,310	22,788,427
Net profit (loss) per share - basic and diluted	18	\$ 0.02	\$ (0.09)	\$ 0.03	\$ (0.32)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Canada House Cannabis Group Inc.
Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficiency)
(formerly Canada House Wellness Group Inc.)
(Unaudited - Expressed in thousands of Canadian Dollars, except for shares and per share amounts)
For the nine months ended April 30, 2023 and 2022

	Note	Number of Shares	Share Capital	Equity Component of Convertible Debentures	Contributed Surplus	Deficit	Total Shareholders' (Equity) Deficiency
Balance as at July 31, 2021		22,788,427	48,685	2,174	15,961	(62,336)	4,484
Share-based compensation		-	-	-	255	-	255
Net loss and comprehensive loss for the period		-	-	-	-	(7,222)	(7,222)
Balance as at April 30, 2022		22,788,427	48,685	2,174	16,216	(69,558)	(2,483)
Balance as at July 31, 2022		22,788,427	48,685	2,174	14,287	(68,899)	(3,753)
Common shares issued pursuant to investment in associates	8	22,779,340	5,846	-	-	-	5,846
Shares issued for finder's fee and service	8	584,797	575	-	-	-	575
Charge related to modification of conversion feature and warrants	13	-	-	-	-	(453)	(453)
Convertible debenture	13	-	-	(1,504)	(1,755)	-	(3,259)
Share-based compensation	16	-	-	-	23	-	23
Net loss and comprehensive loss for the period		-	-	-	-	1,452	1,452
Balance as at April 30, 2023		46,152,564	55,106	670	12,555	(67,900)	431

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Canada House Cannabis Group Inc.
(formerly Canada House Wellness Group Inc.)
Condensed Interim Consolidated Statements of Cash Flows
(Unaudited - Expressed in thousands of Canadian Dollars, except for shares and per share amounts)
For the nine months ended April 30, 2023 and 2022

	Note	April 30 2023	April 30 2022
Cash provided by (used in)			
Operating activities:			
Net profit (loss) and comprehensive profit (loss) for the period		1,452	(7,222)
Add (deduct) items not affecting cash			
Depreciation and amortization	9	1,433	755
Share-based compensation	16	23	255
Non-cash finance and transaction costs		2,237	3,880
Realized fair value loss on sale of inventory		2,236	898
Unrealized fair value (gain) loss in fair value of biological assets		(3,416)	278
Inventory impairment		-	4,000
Share of loss from investment in associates	8	611	-
Loss (gain) on debt settlement and modifications		701	(75)
Change in fair value of financial instruments		(265)	-
Cost of goods sold		89	-
Right-of-use assets amortization		356	273
		5,457	3,042
Changes in non-cash working capital balances related to operations			
Trade and other receivables		(4,704)	(2,701)
Inventory		(1,394)	(2,577)
Biological assets		2,548	986
Prepaid expenses and deposits		(81)	(1,029)
Trade and other payables		(375)	635
Deferred tax liabilities		10	-
Net cash provided by (used in) operating activities		1,461	(1,644)
Investing activities:			
Purchase of property, plant and equipment, net	9	(296)	25
Investment in associates	8	(330)	-
Net cash provided by (used in) investing activities		(626)	25
Financing activities:			
Borrowings		244	2,267
Lease payments		(456)	(454)
Cash interest payments on debenture		-	(97)
Repayment of convertible debentures		(423)	(80)
Mortgage renewal		(60)	-
Repayment of promissory note		(79)	-
Net cash provided by (used in) financing activities		(774)	1,636
Increase in cash during the period		61	17
Cash, beginning of period		450	741
Cash, end of period		511	758

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

1. Nature of operations and going concern uncertainty

Canada House Cannabis Group Inc. (the "**Company**"), formerly Canada House Wellness Group Inc., was incorporated on September 29, 1982 under the *Company Act* of the Province of British Columbia and is listed on the Canadian Securities Exchange (the "**Exchange**") under the symbol CHV (formerly ABA).

These unaudited condensed interim consolidated financial statements of the Company for the three and nine months ended April 30, 2023, comprise the results of the Company and its wholly owned subsidiaries Abba Medix Corp. ("**Abba**"), Canada House Clinics Inc. ("**CHC**"), The Longevity Project Corp. ("**TLP**"), 690050 NB Inc. doing business as Knalysis Technologies ("**Knalysis**"), 2104071 Alberta Inc., which holds the dispensary license in Edmonton, Alberta, IsoCanMed Inc. ("**IsoCanMed**"), a licensed producer in Louiseville, Quebec, that produces high quality medical grade cannabis, and Margaree Health Group Inc. ("**Margaree**"), a medical cannabis clinic dedicated to Veterans in Nova Scotia. Canada House's goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the national medical cannabis markets, the recreational adult-use market in Quebec and across Canada.

Using its own proprietary patient management software developed by Knalysis, CHC provides education services concerning appropriate cannabinoid therapies to patients. Abba initially received its license to produce medical marijuana under the Access to Cannabis for Medical Purposes Regulations, as well as its license to produce cannabis oil and subsequently received an amendment to its Producer's Licence from Health Canada to include the sale and provision of marijuana seeds. In December 2018, Abba received a sales license to sell products from others, but not its own production. In August 2019, Abba was granted an amended license to sell its own production to provincially and territorially authorized provincial retailers and to holders of a license for medical purposes. The Company commenced sale of its Abba branded cannabis flower on October 1, 2019. On June 7, 2021, the Company announced that the registered office of the Company changed to 551 Rue SaintMarc, Louiseville, Quebec from 1773 Bayly Street, Pickering, Ontario.

Going concern uncertainty

The unaudited condensed interim consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. These unaudited condensed interim consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that would be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

For the three and nine months ended April 30, 2023, the Company earned a net profit of \$756 and \$1,452, respectively, and as at April 30, 2023, had an accumulated deficit of \$67,900 and a working capital deficit of \$8,753. Cash flow from operations for the nine months ended April 30, 2023 was \$1,461. Whether, and when, the Company can attain sustained profitability and sustained positive cash flows from operations that is material is subject to material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. The Company will need to raise additional capital in order to fund its planned operations and meet its obligations. While the Company has been successful in obtaining financing to date and believes it will be able to obtain sufficient funds in the future and ultimately achieve sustained profitability and sustained positive cash flows from operations that is material, there can be no assurance that the Company will achieve and sustain profitability and be able to do so in the future that is material for the Company.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

2. Basis of preparation

Statement of compliance

These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, *Interim Financial Reporting* ("IAS34"), as issued by the International Accounting Standards Board ("IASB").

These unaudited condensed interim consolidated financial statements were approved and authorized for issuance in accordance with a resolution of the Board of Directors of the Company on June 29, 2023.

These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company's audited financial statements for the 15-month period ended July 31, 2022.

3. Significant accounting policies

The accounting policies adopted in the preparation of these unaudited condensed interim consolidated financial statements are consistent with those followed in the preparation of the Company's annual consolidated financial statements for the 15-month period ended July 31, 2022, no new standards were adopted other than the Company adopted IAS 28 Investments in Associates to account its new investment in an associate (note 8).

Investment in associates

Associates are all entities over which the Company has significant influence but not control or joint control. This is generally the case where the Company holds between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting (see "Equity Method" below), after initially being recognized at cost. The Company has received unaudited financial statements from MTL and has relied on the information provided by MTL management as input in the preparation of its unaudited condensed interim consolidated financial statements for the three and nine months ended April 30, 2023 and 2022 (note 8).

Equity method

Under the equity method of accounting, investments in associates and joint ventures are initially recognized at cost and adjusted thereafter to recognize the Company's share of the post-acquisition profits or losses of the investee in profit or loss, and the Company's share of movements in other comprehensive income of the investee in other comprehensive income. Dividends received or receivable from associates and joint ventures are recognized as a reduction in the carrying amount of the investment.

Where the Company's share of losses in an equity-accounted investment equals or exceeds its interest in the entity, including any other unsecured long-term receivables, the Company does not recognize further losses, unless it has incurred obligations or made payments on behalf of the other entity.

Unrealized gains on transactions between the Company and its associates and joint ventures are eliminated to the extent of the Company's interest in these entities. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of equity-accounted investees have been changed where necessary to ensure consistency with the policies adopted by the Company. The carrying amount of equity-accounted investments is tested for impairment.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

3. Significant accounting policies (continued)

New and Amended Standards

Amendments to IAS 37: Onerous Contracts - Cost of Fulfilling a Contract

In May 2020, the IASB issued amendments to IAS 37, Provisions, Contingent Liabilities and Contingent Assets, to specify that the cost of fulfilling a contract comprises the costs that relate directly to the contract, and can either be incremental costs of fulfilling that contract or an allocation of other costs that relate directly to fulfilling contracts. The new guidance is effective for annual periods beginning on or after January 1, 2022 and is to be applied to contracts that have unfulfilled obligations as at the beginning of that period. The Company adopted the Amendments to IAS 1 effective August 1, 2022 with no impact to the Company's consolidated financial statements.

IFRS 3 – Business Combinations (“IFRS 3”)

Amendments to IFRS 3 were issued in May 2020, and are effective for annual periods beginning on or after January 1, 2022, with earlier application permitted. The amendments update references within IFRS 3 to the 2018 Conceptual Framework and require that the principles in IAS 27 - Provisions, Contingent Liabilities and Contingent Assets be used to identify liabilities and contingent assets arising from business combination. The Company adopted the Amendments to IFRS 3 effective August 1, 2022 with no impact to the Company's consolidated financial statements.

Future Accounting Pronouncements

The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

Amendments to IAS 1: Classification of Liabilities as Current or Non-Current and Deferral of Effective Date

In January 2020, the IASB issued amendments to IAS 1, Presentation of Financial Statements, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments:

- specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least twelve months; provide that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability; and
- clarify when a liability is considered settled.

On July 15, 2020, the IASB issued a deferral of the effective date for the new guidance by one year to annual reporting periods beginning on or after January 1, 2023 and is to be applied retrospectively. The Company has not yet determined the impact of these amendments on its consolidated financial statements.

IAS 8 – Accounting policies, Changes in accounting estimates and Errors (“IAS 8”)

Amendments to IAS 8 were issued in February 2021, IASB issued Definition of Accounting Estimates, which amends IAS 8. The amendment replaces the definition of accounting estimates. Under the new definition, accounting estimates are “monetary amounts in financial statements that are subject to measurement uncertainty.” The amendment provides clarification to help entities to distinguish between accounting policies and accounting estimates. The amendments are effective for annual periods beginning on or after January 1, 2023.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

3. Significant accounting policies (continued)

IAS 12 – Income Taxes (“IAS 12”)

Amendments to IAS 12 were issued in May 2021, IASB issued Deferred Tax related to Assets and Liabilities arising from a Single Transaction, which amends IAS 12. The amendment narrows the scope of the initial recognition exemption so that it does not apply to transactions that give rise to equal and offset temporary differences. As a result, companies will need to recognize a deferred tax asset and deferred tax liability for temporary differences arising on initial recognition of transactions such as leases and decommissioning obligations. The amendments are effective for annual periods beginning on or after January 1, 2023 and are to be applied retrospectively.

4. Business acquisitions

Margaree Health Group Inc. acquisition

On May 27, 2021 (“**Closing Date**”), the Company's wholly-owned subsidiary, CHC, acquired 100% of the issued and outstanding shares of Margaree Health Group Inc. (“**Margaree**”), a medical cannabis clinic dedicated to veterans in Nova Scotia, for total consideration of \$911. The consideration consisted of \$500 of cash and a three year earn-out measured against Margaree's revenue during the earn-out period, valued at \$411.

The earn-out consideration payable in cash or, at the joint election and agreement of CHC and vendor, shall be payable as follows:

- Payment of 40% of Margaree earn-out revenue for the period from May 1, 2021 to April 30, 2022 during the first week of July 2022;
- Payment of 40% of Margaree earn-out revenue for the period from May 1, 2022 to April 30, 2023 during the first week of July 2023; and
- Payment of 40% of Margaree earn-out revenue for the period from May 1, 2023 to April 30, 2024 during the first week of July 2024.

In the event CHC achieves a Margaree earn-out revenue target of \$350 for period from May 1, 2021 to April 30, 2022, the vendor may elect to amend the earn-out consideration such that is payable as follows:

- Payment of 50% of Margaree earn-out revenue for the period from May 1, 2021 to April 30, 2022 during the first week of July 2022;
- Payment of 50% of Margaree earn-out revenue for the period from May 1, 2022 to April 30, 2023 during the first week of July 2023.

In the event CHC achieves a Margaree earn-out revenue target of \$330 for period from May 1, 2021 to April 30, 2022, \$365 for period from May 1, 2022 to April 30, 2023, or \$400 for period from May 1, 2023 to April 30, 2024, the vendor may elect to amend the earn-out consideration such that the vendor will receive a payment of 45% of Margaree earn-out revenue for the period in which it achieves the earn-out revenue target. On June 30, 2022, the vendor elected 45% of the revenue for three years and CHC paid \$181 of consideration based on 45% of the revenue \$402 earned during the period from May 1, 2021 to April 30, 2022.

For accounting purposes, the consideration payable is valued at the net present value of the estimated earn-out payments using a discount of 10% on the Closing date. On July 31, 2022, the remaining balance of the contingent consideration was revalued to be \$392 based on the increased sales since the acquisition resulting a \$161 expense of remeasurement on contingent consideration in the three months.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

5. Trade and other receivables

The Company's trade and other receivables include the following:

	April 30 2022	July 31, 2022
Trade and other receivables	7,743	3,034
Input taxes and other taxes receivables	19	24
	7,762	3,058

As at April 30, 2023, \$104 (July 31, 2022 - \$14) of allowance for doubtful accounts has been provided for and is not expected to be collected.

6. Inventory

The Company's inventory is comprised of the following:

	April 30 2022	July 31, 2022
Dried cannabis		
- Work-in-process	1,137	2,146
- Finished goods	1,766	1,424
Packaging and consumables	7	7
Other	-	24
	2,910	3,601

As of April 30, 2023, the balance of inventory is comprised of a fair value gain of \$399 (July 31, 2022 - \$163) upon harvest, \$251 (July 31, 2022 - \$1,115) of cost capitalized to inventory and \$2,260 (July 31, 2022 - \$2,323) of purchased products.

Products purchased from other producers are carried at the lower of their carrying amount and net realizable value. Carrying amount approximates the price paid to acquire the products.

Cost of sales for the three and nine months ended April 30, 2023 is \$3,260 and \$8,107 (April 30, 2022 - \$2,750 and \$7,977). The Company assessed there was no impairment to the inventory for the three and nine months ending April 30, 2023 (April 30, 2022 for \$1,259 and \$2,996).

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

7. Biological assets

Biological assets consist of cannabis on plants. The changes in the carrying value of biological assets are as follows:

	\$'000
Balance as at April 30, 2021	692
Production costs capitalized	1,305
Changes in fair value due to biological transformation	(159)
Transferred to inventory upon harvest	(1,754)
Balance as at July 31, 2022	84
Production costs capitalized	1,249
Changes in fair value due to biological transformation	3,416
Transferred to inventory upon harvest	(3,683)
Balance as at April 30, 2023	1,066

The Company measures its biological assets at their fair value less costs to sell. This is determined using a model that estimates the expected harvest yield in grams for plants currently being cultivated, and then multiplies that amount by the expected wholesale selling price.

The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company's method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. Harvested cannabis is transferred from biological assets to inventory at their fair value less costs to sell at harvest.

The biological assets were measured at their fair value less costs to sell of \$1,066 on April 30, 2023 (July 31, 2022 - \$84).

As at April 30, 2023

Significant inputs and assumptions	Inputs	Sensitivity	Effect on biological asset balance
Weighted average selling price per gram	\$1.80	10% Increase or decrease	\$127
Average yield per plant	705 grams	10% Increase or decrease	\$98
Post-harvest cost per gram	\$0.41	10% Increase or decrease	\$29

As at July 31, 2022

Significant inputs and assumptions	Inputs	Sensitivity	Effect on biological asset balance
Weighted average selling price per gram	\$1.75	10% Increase or decrease	\$11
Average yield per plant	586 grams	10% Increase or decrease	\$8
Post-harvest cost per gram	\$0.48	10% Increase or decrease	\$3

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

8. Investment in associates

On August 9, 2021, the Company announced that they have entered into a definitive share exchange agreement for the Company acquisition of all of the issued and outstanding shares of Montréal Cannabis Medical Inc. (“**MTL**”) (herein referred to as the “Transaction”). The Transaction is considered an arm’s length transaction and will constitute a “reverse takeover” of the Company by MTL as it is anticipated that the Company’s shareholders will account for approximately 20% of the combined company post merger.

On August 30, 2022, Canada House Cannabis Group closed the first tranche of its acquisition of MTL. With the closing of the first tranche of the Transaction (the “Initial Closing”) the Company acquired 24.99% of the issued and outstanding shares of MTL in exchange for 49.99% of the issued and outstanding common shares of the Company. Following the completion of the Company’s share consolidation, the Company issued 22,779,340 Common Shares to the shareholders of MTL on the Initial Closing. Subsequent to this transaction, 45,567,767 Common Share of the Company were issued and outstanding. Please see Company’s news release on August 30, 2022.

The parties will proceed to satisfying the closing conditions to the second tranche of the Transaction, namely the preparation of the required audited annual and unaudited interim financial statements and related management’s discussion and analysis of MTL in order for the Company to proceed to a shareholder meeting to approve the Transaction, as required by the rules and policies of the Canadian Securities Exchange. The definitive transaction agreement between the parties provides for the Company to acquire the remaining 75.01% of the issued and outstanding shares of MTL on the second tranche of the Transaction (the “Subsequent Closing”) in exchange for such number of Common Shares that when added to the Common Shares issued on the Initial Closing, is equal to 80.0% of the issued and outstanding common shares of the Company.

At current stage, the Company owns 24.99% of the issued and outstanding shares of MTL and has significant influence over MTL and that is neither a subsidiary nor an interest in a joint venture.

The Company had an enterprise value of \$33,700 as of August 30, 2022, and the 22,779,340 Common Shares (49.99% of the issued and outstanding common shares of the Company issued to acquire the investment in MTL had an enterprise value of \$16,846. Factoring in debt, the Company had an equity value of \$11,693 as of August 30, 2022, and the 22,779,340 Common Shares issued to acquire the investment in MTL had an equity value of \$5,847. \$905 of transaction costs, including finders’ fees and legal costs were incurred to facilitate the Initial Closing and is included within the carrying value of the investment, \$330 of which has been paid by cash, and the remaining balances of \$375 has been settled by the Company’s 394,321 common shares and \$200 has been settled by issuing the Company’s 190,476 common shares.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

8. Investment in associates (continued)

The condensed interim consolidated financial statements include the Company's share of MTL's income, expenses and equity movements. Where the Company transacts with its associates, unrealized profits or losses are eliminated to the extent of the Company's interest in the associate. The carrying value of investment in MTL consists of ⁽¹⁾:

Balance as at July 31, 2022	-
Additions, August 30, 2022	5,847
Transaction costs capitalized	905
Share of net income ⁽²⁾	227
Unrealized gross profit ⁽³⁾	(839)
Balance as at April 30, 2023	6,140

⁽¹⁾ The Company received unaudited Financial Statements from MTL and has relied on this information provided by MTL management as input in the CHV financial statements as represented in Investment in Associates.

⁽²⁾ Represents an estimate of the Company's share of net income based on the latest available information of the investee.

⁽³⁾ Represents the Company's 24.99% of the unrealized gross profit of the unsold inventory MTL purchased from IsoCanMed as of April 30, 2023, based on the latest available information of the investee.

The following table summarizes the financial information of MTL ⁽⁴⁾:

Highlight from the Statements of Financial Position	As at April 30, 2023
Current assets (including cash and cash equivalents)	19,300
Non-current assets	7,875
Current liabilities	(16,730)
Non-current liabilities	(5,656)
Net assets (liabilities) (100%)	4,789
Highlight from the Income Statement	August 30, 2022 to April 30, 2023
Revenue	11,337
Profit from operations	980
Net income and comprehensive income for the period	166
Share of net income (24.99%)	41

⁽⁴⁾ The Company received unaudited Financial Statements from MTL Cannabis and has relied on this information provided by MTL Cannabis management as input in the CHV financial statements as represented in Investment in Associates.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

9. Property, plant and equipment

Cost	Leasehold Improvements	Equipment	Furniture and Fixtures	Building	Land	Total
Balance as at April 30, 2021	7,315	3,770	304	7,886	930	20,205
Additions	50	633	17	1,386	63	2,149
Disposals	(174)	(635)	(11)	(3)	(364)	(1,187)
Balance as at July 31, 2022	7,191	3,768	310	9,269	629	21,167
Additions	-	192	2	57	-	251
Disposals	(5)	(55)	(1)	-	-	(61)
Balance as at April 30, 2023	7,186	3,905	311	9,326	629	21,357

Accumulated depreciation	Leasehold Improvements	Equipment	Furniture and Fixtures	Building	Land	Total
Balance as at April 30, 2021	3,882	1,268	159	309	-	5,618
Depreciation	1,862	724	35	384	-	3,005
Disposals	(108)	(295)	(7)	-	-	(410)
Balance as at July 31, 2022	5,636	1,697	187	693	-	8,213
Depreciation	1,047	364	16	259	-	1,686
Disposals	-	(21)	(1)	-	-	(22)
Balance as at April 30, 2023	6,683	2,040	202	952	-	9,877

Net book value	Leasehold Improvements	Equipment	Furniture and Fixtures	Building	Land	Total
Balance as at July 31, 2022	1,555	2,071	123	8,576	629	12,954
Balance as at April 30, 2023	503	1,865	109	8,374	629	11,480

Of total depreciation for the nine months ended April 30, 2023 totaling \$1,686 (April 30, 2022 - \$1,788), \$114 (April 30, 2022 - \$491) was allocated to biological assets, \$127 (April 30, 2022 - \$572) was allocated to inventory, \$89 (April 30, 2022 - Nil) was allocated to cost of sales, and \$1,356 (April 30, 2022 - \$725) was expensed as depreciation.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

10. Promissory notes

Current

On June 12, 2020, the Company acquired 100% of the outstanding shares of IsoCanMed. As part of the consideration, the Company assumed three promissory notes (the "**ISO Promissory Notes**") in the total amount of \$12,500 payable on or before June 12, 2023 and bearing interest at 5% payable annually. The promissory notes are secured by a general security agreement registered against the asset of IsoCanMed. At the time of acquisition, the promissory notes were valued at \$10,398. As of April 30, 2023, the amortized cost of the three promissory notes is \$11,984.

In July 2022, the maturity date for one of the ISO Promissory Notes in the amount of \$4,167 was extended to June 12, 2024 and two of the ISO Promissory Notes in the total amount of \$8,333 were extended to December 12, 2024. The amendment was treated as a debt modification under IFRS 9 as the terms were not substantially different given the discounted present value of the cash flows under the amended terms is less than 10% different from the discounted present value of the remaining cash flows of the original financial liability. The modification has resulted in a gain of \$1,019 recorded in the consolidated statements of loss and comprehensive loss for the 15-month period ended July 31, 2022.

In December 2022, the Company revised repayment date of one of the ISO Promissory Notes in the amount of \$4,167 from December 12, 2024 to December 12, 2023. The modification resulted in a \$249 loss in the consolidated statements of profit (loss) and comprehensive profit (loss) for the 6-month period ending January 31, 2023. The carrying value of the promissory note of \$4,167 has been classified as current due to the change in the maturity date.

Non-current

The two the ISO Promissory Notes in the total amount of \$8,333 the Company assumed as part of the consideration, one extended to June 12, 2024 and the other extended to December 12, 2024, remained as non-current Debentures. As of April 30, 2023, the amortized cost of the two ISO Promissory Notes is \$7,817.

11. Related party transactions

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling activities of the Company, directly or indirectly, including the Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, Chief Technology Officer and equivalent and Directors.

Compensation expense for the Company's key management personnel for the three and nine months ended April 30, 2023 and 2022 is as follows:

	Three months ended		Nine months ended	
	April 30	April 30	April 30	April 30
	2023	2022	2023	2022
Salaries and wages	418	393	1,195	1,206
Share-based compensation	-	30	13	142
General and administrative	-	18	-	51
	418	441	1,208	1,399

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

11. Related party transactions (continued)

During the nine months ending January 31, 2023, the Company paid \$63 in consulting fees to Industries IsoCan Inc., a company controlled by three shareholders of Canada House, and \$17 of rent to Immeubles IsoCan Inc., a company controlled by the same three shareholders. As of April 30, 2023, the Company owes promissory notes in the total amount of \$12,500 payable (July 31, 2022 - \$12,500) to the same three shareholders. (note 12).

On August 30, 2022, Canada House Cannabis Group closed the first tranche of its acquisition of MTL. With the closing of the first tranche of the Transaction (the "Initial Closing") the Company acquired 24.99% of the issued and outstanding shares of MTL in exchange for 49.99% of the issued and outstanding common shares of the Company. At current stage, the Company owns 24.99% of the issued and outstanding shares of MTL and has significant influence over MTL and that is neither a subsidiary nor an interest in a joint venture. The condensed interim consolidated financial statements include the Company's share of MTL's income, expenses and equity movements. Where the Company transacts with its associates, unrealized profits or losses are eliminated to the extent of the Company's interest in the associate. (note 8)

All related party transactions were in the normal course of operations, measured at the exchange amount.

12. Borrowings

Borrowings consist of the following for the nine months ending April 30, 2023 and year ended July 31 2022:

	April 30, 2023	July 31, 2022
Current		
Loan from vendor ⁽¹⁾	338	334
Loan from other lender ⁽²⁾	899	805
Retrofit loan from Montreal Cannabis Medical Inc. ⁽³⁾	1,336	627
Total current borrowings	2,573	1,766
Non-current		
Retrofit loan from Montreal Cannabis Medical Inc. ⁽³⁾	686	1,013
Loan from Montreal Cannabis Medical Inc. ⁽³⁾	1,151	1,027
Loans from bank ⁽⁴⁾	80	120
Total non-current borrowings	1,917	2,160
Total borrowings	4,490	3,926

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

12. Borrowings (continued)

(1) Loan from vendor

The loan from vendor is a three-year loan of \$313 at 2% interest per annum. The interest is payable annually. The loan is unsecured and matured on October 31, 2021. As of April 30, 2023, the balance of \$338 includes \$313 of principal and \$25 of accrued interest.

(2) Loan from other lender

In October 2021, the Company issued a \$700 principal amount secured debenture (the "**Debenture**") to DMMB (Pty) Holdings Ltd. The Debenture has a two-year term and bears interest at 18% per annum. As of April 30, 2023, the balance of Debenture \$899 includes \$700 of principal and \$199 of accrued interest.

(3) Loans from Montreal Cannabis Medical Inc.

Retrofit loan from Montreal Cannabis Medical Inc.

On December 15, 2021, MTL and IsoCanMed entered into a loan agreement for IsoCanMed to borrow up to \$4,139 from MTL. The Loan amount is to be used by IsoCanMed for the completion of the Retrofit. IsoCanMed borrowed \$1,886 for Phase 1 of the Retrofit as of April 30, 2023 and the total balance of the loan is \$2,022 including \$1,886 of principal and \$136 of interest accrued at 8% per annum. \$1,336 is classified as current and the \$1,151 is classed as non-current to reflect the repayment terms.

The Loan Amount will be made available to IsoCanMed in two tranches as follows:

Tranche 1 (Phases 1 & 2 of the Retrofit)

Tranche 2 (Phases 3 to 7 of the Retrofit)

Each tranche of the Loan Amount will be paid repaid as follows:

Tranche 1:

Commencing on February 3, 2022 and continuing on each monthly anniversary thereafter to September 3, 2022, interest only payments on amounts advanced up to the Tranche 1 loan Amount, at the annual interest rate of 8% per annum, shall be payable by IsoCanMed to MTL.

Commencing on December 3, 2022 and continuing on each three (3) month anniversary thereafter until the Tranche 1 Loan Amount and accrued interest are satisfied in full, IsoCanMed agrees to pay to MTL eight (8) quarterly installments in the amount of \$200,000, with the balance of principal and interest owing to be satisfied in full on the ninth (9th) quarterly anniversary thereafter.

Tranche 2:

Commencing on June 1, 2022 and continuing on each monthly anniversary thereafter to January 1, 2023, interest only payments on amounts advanced up to the Tranche 2 Loan Amount, at the annual interest rate of 8% per annum, shall be payable by IsoCanMed to MTL.

Commencing on April 1, 2023 and continuing on each three (3) month anniversary thereafter until the Tranche 2 Loan Amount and accrued interest are satisfied in full, IsoCanMed agrees to pay to MTL nine (9) quarterly installments in the amount of \$300,000, with the balance of principal and interest owing to be satisfied in full on the tenth (10th) quarterly anniversary thereafter.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

12. Borrowings (continued)

CHV unconditionally and irrevocably guarantees the due and punctual performance and observance by IsoCanMed of its obligations under this Agreement.

Loan from Montreal Cannabis Medical Inc.

During the 15-month period ending July 31, 2022, the Company borrowed \$1,000 from MTL in total at 3% interest per annum. The interest rate was increased to 15% on June 28, 2022. The loan is unsecured and has no specific terms of repayment. As of April 30, 2023, the balance of \$1,150 includes \$1,000 of principal and \$150 of accrued interest.

(4) Loans from bank

The Company borrowed \$120 loans from a Canadian financial institution under the Canada Emergency Business Account ("CEBA") program. The loans are due by December 31, 2024 at the interest rate of 5% per annum starting from January 1, 2024. Repaying the balance of the loans on or before December 31, 2023 will result in loan forgiveness of 25 percent. In anticipation of Knalysis's amalgamation into CHC on May 1, 2023, the Company repaid CEBA loan borrowed by Knalysis and resulted in a loan forgiveness of \$10. As of April 30, 2023, the balance of loans from bank is \$80.

13. Convertible debentures

During the nine months ended April 30, 2023, the changes of the carrying value of the convertible debentures are as follows:

	2020 Debentures	2017 Debentures	Total
Balance as at April 30, 2021	3,115	873	3,988
Principal amount repaid	-	(120)	(120)
Interest payments	-	(165)	(165)
Interest accretion expense	602	462	1,064
Balance as at July 31, 2022	3,717	1,050	4,767
Principal amount repaid	-	(423)	(423)
Interest accretion expense	729	-	729
Balance as at April 30, 2023, prior to modification	4,446	627	5,073
Modification of 2020 Debentures ((ii) and note 26)			
- Increase in carrying value of loan	60	-	60
- Decrease in interest accretion	(21)	-	(21)
Balance as at April 30, 2023, after modification	4,485	627	5,112
Current	-	627	627
Non-current	4,485	-	4,485

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

13. Convertible debentures (continued)

(i) 2017 debentures

On December 5, 2017, the Company issued 8,624 unsecured convertible debenture (“**2017 Debentures**”) units for gross proceeds of \$8,624. Of the gross proceeds received, \$2,000 represented promissory notes that were settled through the issuance of these convertible debenture units, \$75 represented convertible debentures issued to former key management as severance and \$130 represented convertible debentures issued as settlement of \$176 of trade payables. Each 2017 Debentures unit comprises: (i) \$1,000 principal amount of 8.5% unsecured convertible debentures with a maturity date of December 5, 2021; and (ii) 175 detachable common share purchase warrants of the Company (each, a “2017 Warrant”) exercisable into common shares of the Company over a 48 month period at fixed exercise prices. All of the 2017 Warrants have expired with none exercised.

Each 2017 Debenture shall be convertible at the holder’s option into fully paid common shares of the Company at any time prior to the maturity date at a conversion price of \$5.7 per share if converted within the first 12 months following issuance, and at a conversion price of \$12 per share if converted at any time following the date that is 12 months and one day following issuance until maturity. If the volume weighted average closing price of the common shares is greater than or equal to \$10.5 for a period of five consecutive days at any time within the first 12 months of the closing date, the Company has the option to force conversion at \$5.7 per share. If the volume weighted average closing price of the common shares of the Company is greater than or equal to \$15 for a period of five consecutive days at any time after 12 months and before maturity, the Company has the option to force conversion at \$12 per share.

The debentures may be redeemed at any time after issuance on the following basis:

Redemption price	Redemption date
115% of the principal amount plus any accrued and unpaid interest	0–12 months from closing
112% of the principal amount plus any accrued and unpaid interest	12–24 months from closing
109% of the principal amount plus any accrued and unpaid interest	24–36 months from closing
106% of the principal amount plus any accrued and unpaid interest	36–48 months from closing

The interest payable on the debenture is payable monthly in cash.

Transaction costs consisted of \$307 in cash and \$356 of broker warrants with identical terms as the 2017 Warrants.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

13. Convertible debentures (continued)

On initial recognition, the Company allocated the proceeds, net of transaction costs, as follows:

Convertible debentures, liability	1,934
Conversion feature ⁽¹⁾	1,955
Deferred tax liability on conversion feature	705
Warrants	3,368
	<hr/>
	7,962

(1) Upon expiry, \$1,955 related to the conversion feature was reclassified from contributed surplus to deficit.

The value of the conversion option was calculated by subtracting the net present value of the debenture from the face value of the convertible debentures. The net present value of the debenture was calculated using a discount rate of 20.37% over a term of 48 months. As of April 30, 2023, \$627 of the principal amount of the 2017 Debentures remains outstanding and presented within current liabilities.

Prior to the maturity of the 2017 Debentures, the Company corresponded with the remaining holders of 2017 Debentures and proposed Convertible Debenture Amending Agreements (the "**Amending Agreements**") to: i) extend the Maturity Date of the 2017 Debentures to December 5, 2022; ii) increase the interest rate on the outstanding Principal from 8.5% per annum to 18.0% per annum from and after December 5, 2021; iii) remove the conversion right under the Debenture; and, iv) reaffirm the Company's obligations under the 2017 Debentures. The Company did not enter into Amending Agreements with all holders of the 2017 Debentures to extend the Maturity Date of the 2017 Debentures. As of June 29, 2023, all the principal and interest of the 2017 Debentures are due and the holders of the 2017 Debentures may exercise rights to enforce the payment thereof.

(ii) 2020 convertible debenture

On August 8, 2020, the Company closed the strategic investment transaction with Archerwill Investments Inc. ("**Archerwill**"). Archerwill invested \$6,500 in the form of a secured convertible debenture, repaying the 2019 convertible debentures in full. The debenture may be converted into common shares at a price of \$1.5 per common share and bears interest at 8.0%, compound annually, convertible into shares or payable in cash at maturity, at the option of Archerwill. Unless converted earlier, the debentures mature in five years.

Prior to the transaction, Archerwill beneficially owned or had control or direction over 104,066 common shares in the capital of the Company and 165,787 securities of the Company convertible into or exercisable for 165,787 common shares.

Archerwill concurrently received 4.3 million common share purchase warrants ("**2020 Debenture Warrants**"), exercisable at \$1.8 per share for a period of four years, which, if exercised in full, would subsequently increase Archerwill's ownership interest to 28.3% (assuming Archerwill's conversion and exercise in full of all securities it holds in the Company but no other conversions of outstanding securities of the Company). The transaction costs were allocated pro rata based on each individual component's fair value.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

13. Convertible debentures (continued)

On initial recognition, the Company allocated the proceeds, net of \$390 of transaction costs, as follows:

Convertible debenture, liability	2,851
Conversion feature	1,755
Warrants	1,504
	6,110

As of April 30, 2023, \$6,500 of the principal amount of the 2020 convertible debenture remains outstanding and the amortized cost is \$4,485.

In August 2022, the conversion price of the Archerwill Debenture was amended from \$1.50 (pre-consolidation \$0.05) to the lower of \$0.90 and the volume weighted average trading price of the Common Shares of the Resulting Issuer over the first 20 trading days following the resumption of trading of the Common Shares on the Canadian Securities Exchange ("**CSE**"), subject to a minimum price of \$0.50. The excise price of the 4.3 million common share purchase warrants was amended from \$1.80 per share (pre-consolidation \$0.06) to the lower of \$1.20 and 130% of the volume weighted average trading price of the Common Shares of the Resulting Issuer over the first 20 trading days following the resumption of trading of the Common Shares on the CSE.

The modification of the conversion price and the warrant exercise price from a fixed amount to a variable amount has resulted in the conversion feature and warrant no longer being classified as equity. Upon modification, the Company reassessed the fair value of each of the debt, conversion feature and warrant and also reclassified the conversion feature and warrant from equity to financial liabilities on the statement of consolidated financial position. The Company determined the allocation of the carrying value of the host debt instrument, the conversion option derivative, and warrant liability as \$4,086, \$3,463, and \$640, respectively. The fair value of the conversion feature and warrants were assessed using a combination of a Monte Carlo analysis and Black-Scholes model. Key assumptions used in both models were a share price of \$0.61, estimated volatility range of 65% - 70% and a risk-free rate of 3.4% to 3.6%. The fair value of the host debt instrument was fair valued based on a discount rate of 22%.

As at April 30, 2023, the fair values of the conversation option derivative and warrant liability were \$3,142 and \$493, respectively, resulting in a combined gain on change in fair value of \$469.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

14. Mortgage payable

On December 24, 2020, the Company closed a \$2,000 non-dilutive term loan financing at an annual interest rate of 10% (the "Loan"). The Loan is secured by the property and assets of the Company's wholly owned subsidiary, IsoCanMed, in Louiseville, Quebec and is subject to monthly interest-only installments of \$17, with the principal amount repayable at the end of one year. The Loan may be extended for an additional year, at the discretion of the lender, upon 30 days written renewal notice by the Company. The renewal notice will indicate if the Company intends to repay any portion of the loan, up to a maximum of \$1,000. A commitment fee, equal to 4% of the loan amount less the amount repaid, is payable at the each time of renewal. The Loan was extended to January 1, 2024 and interest rate increased to 12% per annum starting from January 1, 2023. The Company paid \$60 of commitment fee at the renewal which is capitalized to the balance of mortgage payable. As of April 30, 2023, the amortized cost of the mortgage is \$1,956.

15. Share capital

(a) Authorized

The authorized share capital of the Company consists of an unlimited number of common shares.

(b) Issued and outstanding

	Common Shares Number	\$	Equity component of convertible debentures \$	Warrants Number	Contributed Surplus \$
Balance as at April 30, 2021	22,788,427	48,685	2,174	10,979,457	15,775
Expiry of conversion feature	-	-	-	-	(1,955)
Warrants expired	-	-	-	(1,939,549)	-
Share-based compensation	-	-	-	-	467
Balance as at July 31, 2022 ^(b)	22,788,427	48,685	2,174	9,039,908	14,287
Common shares issuable in exchange for Investment	22,779,340	5,846	-	-	-
Warrants expired ^(a)	-	-	-	(1,461,813)	-
Charge related to modification of conversion feature and warrants (note 15(ii))	-	-	(1,504)	-	(1,755)
Shares issued for finder's fee and service (note 8)	584,797	575	(1,504)	-	(1,755)
Share-based compensation	-	-	-	-	23
Balance as at April 30, 2023	46,152,564	55,106	670	7,578,095	12,555

(a) During the nine months ending April 30, 2023, 539,063 warrants issued in September 2019 expired without being exercised and 922,750 warrants issued in March 2019 expired without being exercised

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

15. Share capital (continued)

(b) During the 15-month period ending July 31, 2022, the Company extended the expiry date of 3,244,762 (subject to adjustment) outstanding common share purchase warrants of the Company issued on March 4, 2020 (the "Warrants") from March 3, 2023, to December 31, 2026. Aside from the extension of the expiry date, all other terms of the Warrants will remain unchanged.

16. Share-based compensation

The Company has established a stock option plan (the "Option Plan") for directors, officers, employees and consultants of the Company. The Company's Board of Directors determines, among other things, the eligibility of individuals to participate in the Option Plan and the term, vesting periods, and the exercise price of options granted to individuals under the Option Plan.

Each share option converts into one common share of the Company on exercise. No amounts are paid or payable by the individual on receipt of the option. The options carry neither rights to dividends nor voting rights. Options may be exercised at any time from the date of vesting to the date of their expiry.

The Company's Option Plan provides that the number of common shares reserved for issuance may not exceed 10% of the common shares that are outstanding unless the Board of Directors shall have increased such limit by a Board of Directors resolution. In addition, the aggregate number of shares so reserved for issuance to one person may not exceed 5% of the issued and outstanding shares. If any options terminate, expire, or are cancelled as contemplated by the Option Plan, the number of options so terminated, expired or cancelled shall again be available under the Option Plan.

The changes in the number of stock options during the period were as follows:

	Number of Options	Weighted Average Exercise Price (\$)
Balance as at April 30, 2021	1,856,666	2.70
Expired	(80,000)	7.50
Forfeited	(163,333)	3.60
Cancelled	(348,333)	5.70
Balance as at July 31, 2022 and April 30, 2023	1,265,000	1.50

The following table is a summary of the Company's share options outstanding as at April 30, 2023:

Exercising Price (\$)	Number Outstanding	Weighted Average Exercising Contractual Life Years	Number Exercisable
1.50	1,261,667	1.87	1,261,667
4.80	3,333	0.98	3,333
1.50	1,265,000	1.87	1,265,000

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

16. Share-based compensation (continued)

The following table is a summary of the Company's share options outstanding as at July 31, 2022:

Exercising Price (\$)	Number Outstanding	Weighted Average Exercising Contractual Life Years	Number Exercisable
1.50	1,261,667	2.62	1,078,958
4.80	3,333	1.73	3,333
1.50	1,265,000	2.62	1,082,291

The Company recognized Nil and \$23 of share-based compensation expense during the three and nine months ended April 30, 2023 (April 30, 2022 – \$53 and \$255), with a corresponding amount recognized as a contributed surplus.

During the nine months ended April 30, 2023, the Company did not issue any stock options. On May 12, 2022, the Company announced cancellation of 348,333 incentive stock options previously held by certain directors, officers, and employees of the Company.

17. Finance and transaction costs

The finance and transaction costs for the three and nine months ended April 30, 2023 and 2022 are comprised of the follows:

	Three months ended		Nine months ended	
	April 30 2023	April 30 2022	April 30 2023	April 30 2022
Interest and bank charges	675	470	1,953	1,322
Accretion	796	340	1,784	1,164
Transaction costs	-	-	-	241
Total	1,471	810	3,737	2,727

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

18. Profit (loss) per share

Net profit (loss) per common share represents net loss attributable to common shareholders divided by the weighted average number of common shares outstanding during the period.

Diluted profit (loss) per common share is calculated by dividing the applicable net profit (loss) by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the period.

For the three and nine months ended April 30, 2023, diluted profit (loss) per share equals basic profit (loss) per share due to the anti-dilutive effect of convertible debentures, warrants and stock options. The outstanding number and type of securities that could potentially dilute basic net profit (loss) per share in the future, but would have decreased the profit (loss) per share (anti-dilutive) for the periods presented, are as follows:

	April 30, 2023 Number of Shares	July 31, 2022 Number of Shares
Convertible debentures	7,222,222	4,333,333
Warrants	7,578,095	9,039,908
Share options	1,265,000	1,265,000
	16,065,317	14,638,241

19. Nature of expenses

General and administrative expenses for the three and nine months ended April 30, 2023 and 2022 are comprised of:

	Three months ended		Nine months ended	
	April 30 2023	April 30 2022	April 30 2023	April 30 2022
Salaries, wages and consulting fees	1,589	1,669	4,635	5,044
General operating	641	360	1,561	939
Occupancy costs	177	130	445	374
Professional fees	258	82	632	446
	2,665	2,241	7,273	6,803

Sales and marketing expenses for the three and nine months ended April 30, 2023 and 2022 are comprised of:

	Three months ended		Nine months ended	
	April 30 2023	April 30 2022	April 30 2023	April 30 2022
Sales and marketing	353	252	1,002	1,080
Travel	36	7	112	62
	389	259	1,114	1,142

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

20. Commitments and contingencies

Commitments

As at April 30, 2023, the Company is committed under leases for equipment and office space for the following minimum annual rentals:

2022	307
2023	259
2024	221
Thereafter	202
	<hr/>
	989

Contingencies

- (a) The Company and its subsidiary, Abba, were served with a Statement of Claim for damages for the alleged failure to pay invoices in the amount of \$200 plus pre- and post-judgment interest. Pleadings have now closed, and the parties are in the process of scheduling examinations for discovery. Given that examinations for discovery have not yet occurred, it is too early in the process to have a reasonable expectation or evaluation of the Plaintiff's claim, but the Company believes the claim to be without merit.
- (b) On April 15, 2021, Canada House's wholly owned subsidiary, IsoCanMed, was served with an application to initiate proceedings for damages for its alleged failure to pay invoices in the amount of \$304 plus pre and post judgment interest. Prior to the Plaintiff initiating proceedings, IsoCanMed provided the Plaintiff with a list of deficiencies related to the Plaintiff's work installing the HVAC system at IsoCanMed's facility. The list of deficiencies includes the Plaintiff's supply and installation of a chiller which has not yet been put into operation by the Plaintiff. The Plaintiff and IsoCanMed discussed IsoCanMed's payment of the balance owing (approximately \$305) on the total contract value of \$2,300 when the Plaintiff had successfully remedied the outstanding deficiencies in its workmanship. In addition, at the request of the Plaintiff, IsoCanMed provided the Plaintiff with comments on the items it disputed in the Plaintiff's outstanding invoices. After receiving IsoCanMed's requested comments, the Plaintiff halted all communication and proceeded with this application.

IsoCanMed retained external counsel to appear on IsoCanMed's behalf and respond to the application. IsoCanMed's external counsel has filed a Defence and Counterclaim to the Plaintiff's application along with the expert report relied upon in same. At this time, the Plaintiff's defense to IsoCanMed's Counterclaim and any expert evidence to be relied upon by the Plaintiff have not been filed with the Court. Initial discoveries of the Parties related to the Plaintiff's claim and IsoCanMed's Counterclaim have been delayed.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

20. Commitments and contingencies (continued)

- (c) The Company was served with an application to initiate proceedings for damages for its alleged failure to pay indebtedness in the amount of \$65. The Company has retained external counsel to appear on the Company's behalf and respond to the application. It is too early in the process to have a reasonable expectation or evaluation of the plaintiff's claim, but the Company believes the claim to be without merit.
- (d) The Company is in the process of corresponding with the remaining holders of the Company's outstanding Convertible Debentures dated December 5, 2017, some of which were amended by Convertible Debenture Amending Agreements dated as of December 5, 2021 (collectively, the "2017 Debentures"), to propose repayment terms. The Company has not entered into repayment agreements with all holders of the 2017 Debentures. The principal and interest of the 2017 Debentures not subject to repayment agreements is due and payable and the holders of the 2017 Debentures may exercise rights to enforce the payment thereof.

In the ordinary course of business and from time to time, the Company is involved in various other claims related to its ordinary course and conduct of its business. Although such matters cannot be predicted with certainty, management does not consider the Company's exposure to these claims to be material to these consolidated financial statements.

21. Capital management

The Company defines the capital that it manages as the amounts it classifies in share capital, augmented by any amounts raised through the issuance of convertible debentures, promissory notes, borrowings and mortgage payable.

	April 30, 2023	July 31, 2022
Share capital, including equity component of convertible debentures	55,776	50,859
Convertible debentures	5,112	4,767
Financial instruments liabilities	3,635	-
Promissory notes	11,984	10,866
Borrowings	4,490	3,926
Mortgage payable	1,956	2,000
	82,953	72,418

The Company's objectives when managing capital are to ensure that there are adequate capital resources to safeguard the Company's ability to continue as a going concern and to maintain adequate levels of funding to support its ongoing initiatives and business development activities in order to provide returns for its shareholders.

The Company is an early-stage company and is dependent on raising further capital, primarily equity, to fund its capital expenditures and its operating expenses in excess of revenue until such time as it reaches cash break-even. As at April 30, 2023, the Company had raised, net of issuance costs, approximately \$41,570 (July 31, 2022 - \$41,312) by the issuance of common shares, warrants, convertible debentures and long-term debt. The Company may raise additional equity in the future, although there can be no assurance that the Company will be successful in doing so.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

22. Financial instruments and risk management

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from deposits with banks and outstanding receivables. The Company trades only with recognized, creditworthy third parties. The Company performs credit checks for all customers who wish to trade on credit terms. As at April 30, 2023 and July 31, 2022, three customers represented 76% and 42% of the outstanding trade and other receivable balance, respectively. For the nine months ended April 30, 2023, three customers accounted for 49% of revenue (April 30, 2022 – three customers accounted for 48% of revenue).

The Company does not hold any collateral as security, but mitigates this risk by dealing only with what management believes to be financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's exposure to liquidity risk is dependent on the Company's ability to raise additional financing to meet its commitments and sustain operations. The Company mitigates liquidity risk by management of working capital, cash flows and the issuance of share capital.

Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk.

Currency risk

Currency risk is the risk to the Company's earnings that arises from fluctuations of foreign exchange rates. The Company is not exposed to foreign currency exchange risk as it has minimal financial instruments denominated in a foreign currency and substantially all of the Company's transactions are in Canadian dollars, which is also the Company's functional currency.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as at April 30, 2023 as the Company does not have any variable interest rate assets or liabilities.

Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. The Company is not exposed to other price risk as at April 30, 2023.

Fair values

The carrying values of cash, trade and other receivables, trade and other payables, promissory notes, borrowings and convertible debentures approximate the fair values due to the short-term nature of these items or the interest rates and discount rates being at market. The risk of material change in fair value is not considered to be significant due to a relatively short-term nature. The Company does not use derivative financial instruments to manage this risk.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

22. Financial instruments and risk management (continued)

Financial instruments recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The Company categorizes its fair value measurements according to a three-level hierarchy. The hierarchy prioritizes the inputs used by the Company's valuation techniques. A level is assigned to each fair value measurement based on the lowest-level input significant to the fair value measurement in its entirety. The three levels of the fair value hierarchy are defined as follows:

- Level 1 – Unadjusted quoted prices as at the measurement date for identical assets or liabilities in active markets.
- Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
- Level 3 – Significant unobservable inputs that are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value.

During the three and nine months ended April 30, 2023, there were no transfers of amounts between levels.

23. Segmented information

The Company has two reportable and operating segments. The Company cultivates and distributes cannabis related products via federally approved cannabis programs by way of its Licensed Producer business. In addition, Company operates its clinic business through its CHC subsidiary. The Company derives substantially all of its revenue from these two segments. The Company reports segment information based on internal reports used by the Chief Operating Decision maker ("CODM") to make operating and resource decisions and to assess performance. The CODM is the Chief Executive Officer. The CODM makes decisions and assesses performance of the Company on a consolidated basis such that the Company is a single reportable operating segment.

The Company primarily operates in one principal geographical area, Canada, accordingly all of the Company's long lived assets are located in Canada.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

23. Segmented information (continued)

The following table presents details on the Company's segments for the nine months ended April 30, 2023:

Operating segments	CHC	Licensed Producer	Corporate and other	Total
Revenue				
Referral revenue	4,008	-	-	4,008
Product revenue	-	17,330	-	17,330
License revenue and other	58	2,183	1,082	3,323
Less: excise tax	-	(1,516)	-	(1,516)
Net revenue	4,066	17,997	1,082	23,145
Cost of sales	-	8,107	-	8,107
Gross profit before fair value adjustments	4,066	9,890	1,082	15,038
Realized loss on sale of inventory	-	2,236	-	2,236
Realized loss (gain) on biological assets	-	(3,416)	-	(3,416)
Gross profit	4,066	11,070	1,082	16,218
Expenses	2,862	5,475	1,858	10,195
Profit (loss) from operations	1,204	5,595	(776)	6,023
Finance costs	35	711	2,991	3,737
Change in fair value of financial instruments	-	-	(469)	(469)
Share of loss from investment in associates	-	-	611	611
Loss on debt settlement and modifications	-	-	701	701
Loss on assets disposal	-	20	-	20
Profit (loss) before income taxes	1,169	4,864	(4,610)	1,423
Provision for income taxes	100	(129)	-	(29)
Net profit (loss) and comprehensive profit (loss)	1,069	4,993	(4,610)	1,452

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

23. Segmented information (continued)

The following table presents details on the Company's segments for the nine months ended April 30, 2022:

Operating segments	CHC	Licensed Producer	Corporate and other	Total
Revenue				
Referral revenue	3,974	-	-	3,974
Product revenue	-	14,893	-	14,893
License revenue and other	20	413	-	433
Less: excise tax	-	(2,521)	-	(2,521)
Net revenue	3,994	12,785	-	16,779
Cost of sales	2	6,971	-	6,973
Inventory impairment	-	4,000	-	4,000
Gross profit before fair value adjustments	3,992	1,814	-	5,806
Realized loss on sale of inventory	-	898	-	898
Realized loss (gain) on biological assets	-	278	-	278
Gross profit	3,992	638	-	4,630
Expenses	3,906	5,825	(503)	9,228
Profit (loss) from operations	86	(5,187)	503	(4,598)
Finance and transaction costs	622	2,549	(444)	2,727
(Gain) loss on debt settlement	-	(75)	-	(75)
Other expenses	-	2	-	2
Profit (loss) before income taxes	(536)	(7,663)	947	(7,252)
Provision for income taxes	(30)	-	-	(30)
Net profit (loss) and comprehensive profit (loss)	(506)	(7,663)	947	(7,222)

24. Subsequent events

On May 1, 2023, Knalysis was amalgamated into CHC.

On June 28, 2023, the 2020 Convertible Debenture (note 13) terms were further amended as follows:

- Debt Repayment: The 2020 Convertible Debenture was amended to create a proportional payout schedule among any debt repayments to be made on the account of the ISO Promissory Notes (note 10) or shareholder loans advanced to MTL (the "MTL Shareholder Loans") such that the Company shall not be entitled to repay any principal under the ISO Promissory Notes or the MTL Shareholder Loans unless, contemporaneously with such repayment, the Company repays the obligations under the 2020 Convertible Debenture such that, on a proportionate basis as between payments made on the ISO Promissory Notes, the MTL Shareholders Loans and the 2020 Convertible Debenture, for each \$1.00 paid toward principal: (i) 0.50 shall be paid towards principal obligations due under the ISO Promissory Notes; (ii) \$0.25 shall be paid towards the 2020 Convertible Debenture; and (iii) \$0.25 shall be paid towards principal obligations due under the MTL Shareholder Loans.

Canada House Cannabis Group Inc.

(formerly Canada House Wellness Group Inc.)

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in thousands of Canadian dollars, except for shares and per share amounts)

For the three and nine months ended April 30, 2023 and 2022

24. Subsequent events (continued)

- **Mandatory Debt Prepayment:** The 2020 Convertible Debenture was amended to require that the Company repay the obligations thereunder at any time prior to maturity thereof, the impact of which is that the issuance of the Archerwill Prepayment Warrants will be triggered.
- **Extension of the Term of the Archerwill Prepayment Warrants:** The 2020 Convertible Debenture was amended to extend the term of any Archerwill Prepayment Warrants by two years so that the expiry date shall be August 5, 2027 rather than August 5, 2025.
- **Cancellation of the 2020 Debenture Warrants and the Issuance of the 2020 Debenture Consideration Warrants.** The 2020 Debenture Warrants are to be cancelled and the 2020 Debenture Consideration Warrants will be issued. The two warrant instruments provide for the same number of Common Shares underlying the exercise thereof and the same Exercise Price. However, 60% of the 2020 Debenture Consideration Warrants (2,600,000 2020 Debenture Consideration Warrants) will not vest if the Amended Conversion price is equal to or less than \$0.65 per Common Share and the term of the 2020 Debenture Consideration Warrants will expire on August 5, 2027 whereas the 2020 Debenture Warrants were to expire on August 5, 2025.

The above amendments will become effective on the Tranche Two Closing and are subject to various conditions and covenants, including the passing of the Archerwill Amendment Resolution and any necessary regulatory approval of the amendments.

On June 28, 2023, the Company, MTL and the shareholders of MTL entered into a second restated share exchange agreement with respect to the Transaction, which waived certain conditions to closing and provided certain interim period funding supports to the Company.